- Zacks•49 minutes ago
Exelixis (EXEL) could be good choice for investors as it is seeing decent short-term momentum and positive earnings estimate revisions.
- Business Wire•3 hours ago
Exelixis, Inc. today announced that accomplished biopharmaceutical executive Julie Anne Smith has been elected to the company’s Board of Directors. Ms. Smith’s appointment took effect on September 22, 2016.
- Business Wire•3 hours agoExelixis Announces Collaborator Daiichi Sankyo’s Initiation of Phase 3 Clinical Development for CS-3150, a Selective Mineralocorticoid Receptor Antagonist
Exelixis, Inc. today announced that its partner Daiichi Sankyo Company, Limited has initiated a phase 3 pivotal trial to evaluate CS-3150 ), an oral, non-steroidal, selective mineralocorticoid receptor antagonist, as a treatment for essential hypertension in Japanese patients.
Exelixis, Inc. (EXEL)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||15.22 x 200|
|Ask||15.25 x 500|
|Day's Range||14.71 - 14.97|
|52wk Range||3.55 - 15.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-17.73|
|Avg Vol (3m)||5,923,541|
|Dividend & Yield||N/A (N/A)|